Prognostic value of non-cytotoxic HLA-antibodies for kidney transplantatio

• Conditions: N18.4; N18.5; Chronic kidney disease, stage 4; Chronic kidney disease, stage 5

• Registration Number: DRKS00009229
• Lead Sponsor: Institut für TransfusionsmedizinUniversitätsklinikum Schleswig-Holstein

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-08-13
• Study Completion: 2018-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 4233

Inclusion Criteria

Kidney transplantation

Exclusion Criteria

None

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of antibody-mediated rejection during the first 6 months post transplantation

Secondary Outcome Measures

Name	Time	Method
1) Death-censored transplant survival<br>2) Patient survival<br>3) Creatinine-value<br>4) Glomerular filtration rate<br>5) Intensity of immunosuppression<br>6) Incidence of delayed graft function<br><br>(Time points: at hospital discharge, 6 months post transplantation, 1 year and yearly post transplantation)